ISRCTN58221074 https://doi.org/10.1186/ISRCTN58221074

Effect of brimonidine, measured with the Nerve Fibre Analyser, in patients with acute ischaemic optic neuropathy

Submission date 20/12/2005	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 20/12/2005	**Overall study status** Completed	
Last Edited 05/11/2008	**Condition category** Eye Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr H G Lemij

Contact details
Oogziekenhuis Rotterdam
Schiedamsevest 180
Rotterdam
Netherlands
3011 BH
+31 (0)10 401 7777
Lemij@oogziekenhuis.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
OZR-2000-07; NTR139

Study information

Scientific Title

Acronym
AION

Study objectives
Administration of brimonidine eye drops in patients with acute ischaemic optic neuropathy (AION) reduces loss of vision.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Received from local medical ethics committee

Study design
Randomised, double-blind, placebo controlled, parallel group, two-arm trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Acute ischaemic optic neuropathy

Interventions
Topical treatment with brimonidine (0.5%) eye drops.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Brimonidine

Primary outcome measure
Thickness of peripapillary nerve fiber layer.

Secondary outcome measures
No secondary outcome measures

Overall study start date
01/02/2001

Completion date
01/08/2002

Eligibility

Key inclusion criteria
Arteric or non-arteric AION

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
20

Key exclusion criteria
1. Onset of symptoms greater than 5 days ago at presentation
2. Inability to undergo GDx or HFA measurement

Date of first enrolment
01/02/2001

Date of final enrolment
01/08/2002

Locations

Countries of recruitment
Netherlands

Study participating centre

Oogziekenhuis Rotterdam
Rotterdam
Netherlands
3011 BH

Sponsor information

Organisation
Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)

Sponsor details
Schiedamsevest 180
Rotterdam
Netherlands
3011 BH
+31 (0)10 401 77 77
info@oogziekenhuis.nl

Sponsor type
Hospital/treatment centre

ROR
https://ror.org/02hjc7j46

Funder(s)

Funder type
Research organisation

Funder Name
Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration